CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin and non-Hodgkin lymphoma.
  
  LEARNING OBJECTIVES

  • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of diffuse large B-cell lymphoma (DLBCL).
  • Recall published research data and other clinical factors in the best-practice selection, sequencing or combination of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of newly diagnosed and R/R mantle cell lymphoma (MCL) to determine the current and potential utility in clinical practice.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients for whom this approach may be appropriate.
  • Design a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of FL, MCL, HL and DLBCL to support quality of life and continuation of therapy.
  • Recall new data with investigational agents and strategies demonstrating promising activity in various lymphoma subtypes, and discuss clinical trial opportunities with eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  John Kuruvilla, MD
  Hematologist, Princess Margaret Cancer Centre
  Associate Professor, University of Toronto
  Toronto, Ontario, Canada
  
  Consulting Agreements: AbbVie Inc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Seagen Inc; Honoraria: Amgen Inc, Antengene, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc, Seagen Inc, TG Therapeutics Inc.
  
  John P Leonard, MD
  Richard T Silver Distinguished Professor of Hematology and Medical Oncology
  Associate Dean for Clinical Research
  Executive Vice Chair, Joan and Sanford I Weill Department of Medicine
  Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: ADC Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Karyopharm Therapeutics, MEI Pharma Inc, MorphoSys, Nordic Nanovector, Novartis, Roche Laboratories Inc, Sutro Biopharma; Data and Safety Monitoring Board/Committee: Biotest Pharmaceuticals Corporation, Bristol-Myers Squibb Company.
  
  Michael E Williams, MD, ScM
  Byrd S Leavell Professor of Medicine
  Chief, Hematology/Oncology Division
  Physician Lead, Cancer Service Line
  University of Virginia School of Medicine
  Charlottesville, Virginia
  
  Advisory Committee: AbbVie Inc; Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Speakers Bureau: Xian Janssen Pharmaceutical Ltd.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics and Seagen Inc.
  
  Release date: April 2021
  Expiration date: April 2022